{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,11]],"date-time":"2026-03-11T13:34:21Z","timestamp":1773236061971,"version":"3.50.1"},"reference-count":75,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2014,7,10]],"date-time":"2014-07-10T00:00:00Z","timestamp":1404950400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Curr. Treat. Options in Oncol."],"published-print":{"date-parts":[[2014,9]]},"DOI":"10.1007\/s11864-014-0298-0","type":"journal-article","created":{"date-parts":[[2014,7,9]],"date-time":"2014-07-09T07:08:19Z","timestamp":1404889699000},"page":"443-455","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Optimal Treatment Strategies for Anal Cancer"],"prefix":"10.1007","volume":"15","author":[{"given":"Shahab","family":"Ahmed","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cathy","family":"Eng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2014,7,10]]},"reference":[{"issue":"11","key":"298_CR1","doi-asserted-by":"crossref","first-page":"792","DOI":"10.1056\/NEJM200003163421107","volume":"342","author":"DP Ryan","year":"2000","unstructured":"Ryan DP, Compton CC, Mayer RJ. Carcinoma of the anal canal. N Engl J Med. 2000;342(11):792\u2013800.","journal-title":"N Engl J Med"},{"key":"298_CR2","unstructured":"ACS, A.C.S. Cancer Facts & Figures 2014. 2014."},{"issue":"2","key":"298_CR3","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1016\/j.virol.2011.09.018","volume":"421","author":"MK Thomas","year":"2011","unstructured":"Thomas MK et al. Dominant role of HPV16 E7 in anal carcinogenesis. Virology. 2011;421(2):114\u20138.","journal-title":"Virology"},{"issue":"4","key":"298_CR4","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1097\/00001622-200007000-00011","volume":"12","author":"DP Ryan","year":"2000","unstructured":"Ryan DP, Mayer RJ. Anal carcinoma: histology, staging, epidemiology, treatment. Curr Opin Oncol. 2000;12(4):345\u201352.","journal-title":"Curr Opin Oncol"},{"issue":"1","key":"298_CR5","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1038\/sj.bjc.6603175","volume":"95","author":"DH Brewster","year":"2006","unstructured":"Brewster DH, Bhatti LA. Increasing incidence of squamous cell carcinoma of the anus in Scotland, 1975-2002. Br J Cancer. 2006;95(1):87\u201390.","journal-title":"Br J Cancer"},{"key":"298_CR6","doi-asserted-by":"crossref","unstructured":"Edge ST, Byrd DR, Compton CC, Fritz AG, Greene FL, Trotti A. Anus. In: AJCC Cancer Staging Manual. 7th edition. Springer. 2010;165\u201373.","DOI":"10.1007\/978-0-387-88441-7_15"},{"issue":"2","key":"298_CR7","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1002\/cncr.20365","volume":"101","author":"JR Daling","year":"2004","unstructured":"Daling JR et al. Human papillomavirus, smoking, and sexual practices in the etiology of anal cancer. Cancer. 2004;101(2):270\u201380.","journal-title":"Cancer"},{"issue":"19","key":"298_CR8","doi-asserted-by":"crossref","first-page":"1350","DOI":"10.1056\/NEJM199711063371904","volume":"337","author":"M Frisch","year":"1997","unstructured":"Frisch M et al. Sexually transmitted infection as a cause of anal cancer. N Engl J Med. 1997;337(19):1350\u20138.","journal-title":"N Engl J Med"},{"issue":"3","key":"298_CR9","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1016\/j.ygyno.2009.05.006","volume":"114","author":"W Jimenez","year":"2009","unstructured":"Jimenez W et al. Presumed previous human papillomavirus (HPV) related gynecological cancer in women diagnosed with anal cancer in the province of Ontario. Gynecol Oncol. 2009;114(3):395\u20138.","journal-title":"Gynecol Oncol"},{"issue":"3","key":"298_CR10","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1002\/ijc.25080","volume":"127","author":"KG Sunesen","year":"2010","unstructured":"Sunesen KG et al. Immunosuppressive disorders and risk of anal squamous cell carcinoma: a nationwide cohort study in Denmark, 1978-2005. Int J Cancer. 2010;127(3):675\u201384.","journal-title":"Int J Cancer"},{"issue":"5","key":"298_CR11","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1634\/theoncologist.12-5-524","volume":"12","author":"HE Uronis","year":"2007","unstructured":"Uronis HE, Bendell JC. Anal cancer: an overview. Oncologist. 2007;12(5):524\u201334.","journal-title":"Oncologist"},{"key":"298_CR12","unstructured":"National Cancer Institute, N., Anal Cancer Treatment. 2014."},{"key":"298_CR13","first-page":"19","volume":"3","author":"YJ Chin","year":"2013","unstructured":"Chin YJ, Hong ST, Wo JY. Anal cancer: current and future treatment strategies. Gastrointest Cancer: Targets and Ther. 2013;3:19\u201327. This article is informative of current anal cancer treatment options.","journal-title":"Gastrointest Cancer: Targets and Ther"},{"issue":"6","key":"298_CR14","doi-asserted-by":"crossref","first-page":"1285","DOI":"10.1002\/1097-0142(19840315)53:6<1285::AID-CNCR2820530611>3.0.CO;2-N","volume":"53","author":"DB Frost","year":"1984","unstructured":"Frost DB et al. Epidermoid cancer of the anorectum. Cancer. 1984;53(6):1285\u201393.","journal-title":"Cancer"},{"issue":"10","key":"298_CR15","doi-asserted-by":"crossref","first-page":"1727","DOI":"10.1002\/1097-0142(196710)20:10<1727::AID-CNCR2820201024>3.0.CO;2-1","volume":"20","author":"RG Klotz Jr","year":"1967","unstructured":"Klotz Jr RG, Pamukcoglu T, Souilliard DH. Transitional cloacogenic carcinoma of the anal canal. Clinicopathologic study of three hundred seventy-three cases. Cancer. 1967;20(10):1727\u201345.","journal-title":"Cancer"},{"key":"298_CR16","unstructured":"NCI. SEER Stat Fact Sheets: Anal Cancer. 2013; Available from: ( http:\/\/seer.cancer.gov\/statfacts\/html\/anus.html )."},{"issue":"7","key":"298_CR17","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1007\/BF02238600","volume":"36","author":"ND Nigro","year":"1993","unstructured":"Nigro ND, Vaitkevicius VK, Considine Jr B. Combined therapy for cancer of the anal canal: a preliminary report, 1974. Dis Colon Rectum. 1993;36(7):709\u201311.","journal-title":"Dis Colon Rectum"},{"issue":"6","key":"298_CR18","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.1007\/s10350-004-0934-z","volume":"48","author":"H Sato","year":"2005","unstructured":"Sato H, Koh PK, Bartolo DC. Management of anal canal cancer. Dis Colon Rectum. 2005;48(6):1301\u201315.","journal-title":"Dis Colon Rectum"},{"issue":"5","key":"298_CR19","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.1016\/0360-3016(91)90265-6","volume":"21","author":"BJ Cummings","year":"1991","unstructured":"Cummings BJ et al. Epidermoid anal cancer: treatment by radiation alone or by radiation and 5-fluorouracil with and without mitomycin C. Int J Radiat Oncol Biol Phys. 1991;21(5):1115\u201325.","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"5","key":"298_CR20","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1007\/BF02049397","volume":"35","author":"J Papillon","year":"1992","unstructured":"Papillon J, Chassard JL. Respective roles of radiotherapy and surgery in the management of epidermoid carcinoma of the anal margin. Series of 57 patients. Dis Colon Rectum. 1992;35(5):422\u20139.","journal-title":"Dis Colon Rectum"},{"issue":"8","key":"298_CR21","doi-asserted-by":"crossref","first-page":"1378","DOI":"10.1002\/1097-0142(19830415)51:8<1378::AID-CNCR2820510810>3.0.CO;2-F","volume":"51","author":"MS Flam","year":"1983","unstructured":"Flam MS et al. Definitive nonsurgical therapy of epithelial malignancies of the anal canal. A report of 12 cases. Cancer. 1983;51(8):1378\u201387.","journal-title":"Cancer"},{"key":"298_CR22","doi-asserted-by":"crossref","unstructured":"Epidermoid anal cancer: results from the UKCCCR randomised trial of radiotherapy alone versus radiotherapy, 5-fluorouracil, and mitomycin. UKCCCR Anal Cancer Trial Working Party. UK Co-ordinating Committee on Cancer Research. Lancet. 1996;348(9034):1049\u201354. doi: 10.1016\/S0140-6736(96)03409-5 .","DOI":"10.1016\/S0140-6736(96)03409-5"},{"issue":"5","key":"298_CR23","doi-asserted-by":"crossref","first-page":"2040","DOI":"10.1200\/JCO.1997.15.5.2040","volume":"15","author":"H Bartelink","year":"1997","unstructured":"Bartelink H et al. Concomitant radiotherapy and chemotherapy is superior to radiotherapy alone in the treatment of locally advanced anal cancer: results of a phase III randomized trial of the European Organization for Research and Treatment of Cancer Radiotherapy and Gastrointestinal Cooperative Groups. J Clin Oncol. 1997;15(5):2040\u20139.","journal-title":"J Clin Oncol"},{"issue":"7","key":"298_CR24","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1038\/sj.bjc.6605605","volume":"102","author":"J Northover","year":"2010","unstructured":"Northover J et al. Chemoradiation for the treatment of epidermoid anal cancer: 13-year follow-up of the first randomised UKCCCR Anal Cancer Trial (ACT I). Br J Cancer. 2010;102(7):1123\u20138.","journal-title":"Br J Cancer"},{"issue":"16","key":"298_CR25","doi-asserted-by":"crossref","first-page":"1941","DOI":"10.1200\/JCO.2011.35.4837","volume":"30","author":"D Peiffert","year":"2012","unstructured":"Peiffert D et al. Induction chemotherapy and dose intensification of the radiation boost in locally advanced anal canal carcinoma: final analysis of the randomized UNICANCER ACCORD 03 trial. J Clin Oncol. 2012;30(16):1941\u20138.","journal-title":"J Clin Oncol"},{"issue":"16","key":"298_CR26","doi-asserted-by":"crossref","first-page":"1914","DOI":"10.1001\/jama.299.16.1914","volume":"299","author":"JA Ajani","year":"2008","unstructured":"Ajani JA et al. Fluorouracil, mitomycin, and radiotherapy vs fluorouracil, cisplatin, and radiotherapy for carcinoma of the anal canal: a randomized controlled trial. JAMA. 2008;299(16):1914\u201321.","journal-title":"JAMA"},{"issue":"35","key":"298_CR27","doi-asserted-by":"crossref","first-page":"4344","DOI":"10.1200\/JCO.2012.43.8085","volume":"30","author":"LL Gunderson","year":"2012","unstructured":"Gunderson LL et al. Long-term update of US GI intergroup RTOG 98-11 phase III trial for anal carcinoma: survival, relapse, and colostomy failure with concurrent chemoradiation involving fluorouracil\/mitomycin versus fluorouracil\/cisplatin. J Clin Oncol. 2012;30(35):4344\u201351. This contains the recent updates on RTOG 98-11 trial.","journal-title":"J Clin Oncol"},{"key":"298_CR28","doi-asserted-by":"crossref","unstructured":"Glynne Jones R, et al. Optimum time to assess complete clinical response (CR) following chemoradiation (CRT) using mitomycin (MMC) or cisplatin (CisP), with or without maintenance CisP\/5FU in squamous cell carcinoma of the anus: results of ACT II. 2012 ASCO Annual Meeting Abstract.J Clin Oncol. 2012, 30 (suppl 15; abstr 4004). Available from: http:\/\/meeting.ascopubs.org\/cgi\/content\/abstract\/30\/15_suppl\/4004 . This study assesses the complete response rate at different time points following combined modality therapy.","DOI":"10.1200\/jco.2012.30.15_suppl.4004"},{"issue":"6","key":"298_CR29","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1016\/S1470-2045(13)70086-X","volume":"14","author":"RD James","year":"2013","unstructured":"James RD et al. Mitomycin or cisplatin chemoradiation with or without maintenance chemotherapy for treatment of squamous-cell carcinoma of the anus (ACT II): a randomised, phase 3, open-label, 2 x 2 factorial trial. Lancet Oncol. 2013;14(6):516\u201324. This is a pivotal study in the management of squamous cell carcinoma of the anal canal.","journal-title":"Lancet Oncol"},{"issue":"21","key":"298_CR30","doi-asserted-by":"crossref","first-page":"3769","DOI":"10.1002\/cncr.28296","volume":"119","author":"C Eng","year":"2013","unstructured":"Eng C et al. Long-term results of weekly\/daily cisplatin-based chemoradiation for locally advanced squamous cell carcinoma of the anal canal. Cancer. 2013;119(21):3769\u201375. This review supports the use of cisplatin in combination therapy for locally advanced squamous cell carcinoman of the anal canal.","journal-title":"Cancer"},{"issue":"31","key":"298_CR31","doi-asserted-by":"crossref","first-page":"4873","DOI":"10.1200\/JCO.2007.11.5501","volume":"25","author":"MK Kam","year":"2007","unstructured":"Kam MK et al. Prospective randomized study of intensity-modulated radiotherapy on salivary gland function in early-stage nasopharyngeal carcinoma patients. J Clin Oncol. 2007;25(31):4873\u20139.","journal-title":"J Clin Oncol"},{"issue":"3","key":"298_CR32","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1016\/j.ijrobp.2005.02.050","volume":"63","author":"JB Ashman","year":"2005","unstructured":"Ashman JB et al. Whole pelvic radiotherapy for prostate cancer using 3D conformal and intensity-modulated radiotherapy. Int J Radiat Oncol Biol Phys. 2005;63(3):765\u201371.","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"1","key":"298_CR33","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.ijrobp.2012.09.023","volume":"86","author":"LA Kachnic","year":"2013","unstructured":"Kachnic LA et al. RTOG 0529: a phase 2 evaluation of dose-painted intensity modulated radiation therapy in combination with 5-fluorouracil and mitomycin-C for the reduction of acute morbidity in carcinoma of the anal canal. Int J Radiat Oncol Biol Phys. 2013;86(1):27\u201333.","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"2","key":"298_CR34","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1016\/j.ijrobp.2005.02.030","volume":"63","author":"MT Milano","year":"2005","unstructured":"Milano MT et al. Intensity-modulated radiation therapy (IMRT) in the treatment of anal cancer: toxicity and clinical outcome. Int J Radiat Oncol Biol Phys. 2005;63(2):354\u201361.","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"29","key":"298_CR35","doi-asserted-by":"crossref","first-page":"4581","DOI":"10.1200\/JCO.2007.12.0170","volume":"25","author":"JK Salama","year":"2007","unstructured":"Salama JK et al. Concurrent chemotherapy and intensity-modulated radiation therapy for anal canal cancer patients: a multicenter experience. J Clin Oncol. 2007;25(29):4581\u20136.","journal-title":"J Clin Oncol"},{"issue":"1","key":"298_CR36","doi-asserted-by":"crossref","first-page":"123","DOI":"10.6004\/jnccn.2010.0008","volume":"8","author":"JM Pepek","year":"2010","unstructured":"Pepek JM, Willett CG, Czito BG. Radiation therapy advances for treatment of anal cancer. J Natl Compr Cancer Netw. 2010;8(1):123\u20139.","journal-title":"J Natl Compr Cancer Netw"},{"issue":"15","key":"298_CR37","doi-asserted-by":"crossref","first-page":"3342","DOI":"10.1002\/cncr.25901","volume":"117","author":"JG Bazan","year":"2011","unstructured":"Bazan JG et al. Intensity-modulated radiation therapy versus conventional radiation therapy for squamous cell carcinoma of the anal canal. Cancer. 2011;117(15):3342\u201351.","journal-title":"Cancer"},{"issue":"1","key":"298_CR38","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/j.ijrobp.2010.09.030","volume":"82","author":"LA Kachnic","year":"2012","unstructured":"Kachnic LA et al. Dose-painted intensity-modulated radiation therapy for anal cancer: a multi-institutional report of acute toxicity and response to therapy. Int J Radiat Oncol Biol Phys. 2012;82(1):153\u20138.","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"6","key":"298_CR39","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1016\/j.clon.2011.09.014","volume":"24","author":"SG DeFoe","year":"2012","unstructured":"DeFoe SG et al. Concurrent chemotherapy and intensity-modulated radiation therapy for anal carcinoma\u2013clinical outcomes in a large National Cancer Institute-designated integrated cancer centre network. Clin Oncol (R Coll Radiol). 2012;24(6):424\u201331.","journal-title":"Clin Oncol (R Coll Radiol)"},{"key":"298_CR40","unstructured":"Mitchell MP, et al. Intensity-modulated radiation therapy with concurrent chemotherapy for anal cancer: outcomes and toxicity. Am J Clin Oncol. 2013. This article describes the role of IMRT and its toxicity in the management of localized squamous cell carcinoma of the anal canal."},{"issue":"2","key":"298_CR41","first-page":"39","volume":"6","author":"MD Chuong","year":"2013","unstructured":"Chuong MD et al. Intensity-modulated radiation therapy vs. 3D conformal radiation therapy for squamous cell carcinoma of the anal canal. Gastrointest Cancer Res. 2013;6(2):39\u201345.","journal-title":"Gastrointest Cancer Res"},{"issue":"1","key":"298_CR42","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1007\/s10350-004-0746-1","volume":"48","author":"L Ghouti","year":"2005","unstructured":"Ghouti L et al. Salvage abdominoperineal resection after failure of conservative treatment in anal epidermoid cancer. Dis Colon Rectum. 2005;48(1):16\u201322.","journal-title":"Dis Colon Rectum"},{"issue":"3","key":"298_CR43","first-page":"443","volume":"16","author":"PJ Nilsson","year":"2006","unstructured":"Nilsson PJ et al. Prognostic significance of Cyclin A in epidermoid anal cancer. Oncol Rep. 2006;16(3):443\u20139.","journal-title":"Oncol Rep"},{"issue":"2","key":"298_CR44","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1245\/ASO.2005.03.100","volume":"12","author":"DB Chessin","year":"2005","unstructured":"Chessin DB et al. Rectus flap reconstruction decreases perineal wound complications after pelvic chemoradiation and surgery: a cohort study. Ann Surg Oncol. 2005;12(2):104\u201310.","journal-title":"Ann Surg Oncol"},{"issue":"4","key":"298_CR45","doi-asserted-by":"crossref","first-page":"694","DOI":"10.1016\/j.jamcollsurg.2007.12.007","volume":"206","author":"CE Butler","year":"2008","unstructured":"Butler CE, Gundeslioglu AO, Rodriguez-Bigas MA. Outcomes of immediate vertical rectus abdominis myocutaneous flap reconstruction for irradiated abdominoperineal resection defects. J Am Coll Surg. 2008;206(4):694\u2013703.","journal-title":"J Am Coll Surg"},{"issue":"1","key":"298_CR46","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1245\/s10434-008-0208-4","volume":"16","author":"KG Sunesen","year":"2009","unstructured":"Sunesen KG et al. Perineal healing and survival after anal cancer salvage surgery: 10-year experience with primary perineal reconstruction using the vertical rectus abdominis myocutaneous (VRAM) flap. Ann Surg Oncol. 2009;16(1):68\u201377.","journal-title":"Ann Surg Oncol"},{"issue":"5","key":"298_CR47","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1097\/SLA.0b013e3181bce334","volume":"250","author":"JH Lefevre","year":"2009","unstructured":"Lefevre JH et al. Abdomino-perineal resection for anal cancer: impact of a vertical rectus abdominis myocutaneus flap on survival, recurrence, morbidity, and wound healing. Ann Surg. 2009;250(5):707\u201311.","journal-title":"Ann Surg"},{"issue":"1","key":"298_CR48","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.ciresp.2010.10.002","volume":"89","author":"JE Nunez","year":"2011","unstructured":"Nunez JE et al. Abdominoperineal resection in anal cancer: reconstruction of the perineum with a myocutaneous flap from the anterior rectus abdominis muscle. Cir Esp. 2011;89(1):31\u20136.","journal-title":"Cir Esp"},{"key":"298_CR49","first-page":"756591","volume":"2012","author":"A Dewdney","year":"2012","unstructured":"Dewdney A, Rao S. Metastatic squamous cell carcinoma of the anus: time for a shift in the treatment paradigm? ISRN Oncol. 2012;2012:756591. This informative reference describes the development on metastatic squamous cell cracinoma of the anal canal.","journal-title":"ISRN Oncol"},{"issue":"3","key":"298_CR50","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1007\/BF00263905","volume":"15","author":"N Wilking","year":"1985","unstructured":"Wilking N et al. Phase II study of combination bleomycin, vincristine and high-dose methotrexate (BOM) with leucovorin rescue in advanced squamous cell carcinoma of the anal canal. Cancer Chemother Pharmacol. 1985;15(3):300\u20132.","journal-title":"Cancer Chemother Pharmacol"},{"issue":"3","key":"298_CR51","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1002\/1097-0142(20010801)92:3<642::AID-CNCR1365>3.0.CO;2-Z","volume":"92","author":"JD Hainsworth","year":"2001","unstructured":"Hainsworth JD et al. Paclitaxel, carboplatin, and long-term continuous infusion of 5-fluorouracil in the treatment of advanced squamous and other selected carcinomas: results of a Phase II trial. Cancer. 2001;92(3):642\u20139.","journal-title":"Cancer"},{"issue":"5","key":"298_CR52","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1007\/s10637-006-7667-x","volume":"24","author":"M Jhawer","year":"2006","unstructured":"Jhawer M et al. Phase II study of mitomycin-C, adriamycin, cisplatin (MAP) and Bleomycin-CCNU in patients with advanced cancer of the anal canal: an eastern cooperative oncology group study E7282. Investig New Drugs. 2006;24(5):447\u201354.","journal-title":"Investig New Drugs"},{"issue":"10","key":"298_CR53","first-page":"861","volume":"86","author":"C Faivre","year":"1999","unstructured":"Faivre C et al. 5-fluorouracile and cisplatinum combination chemotherapy for metastatic squamous-cell anal cancer. Bull Cancer. 1999;86(10):861\u20135.","journal-title":"Bull Cancer"},{"issue":"2","key":"298_CR54","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1016\/S0002-9343(89)80702-8","volume":"87","author":"JA Ajani","year":"1989","unstructured":"Ajani JA et al. Combination of cisplatin plus fluoropyrimidine chemotherapy effective against liver metastases from carcinoma of the anal canal. Am J Med. 1989;87(2):221\u20134.","journal-title":"Am J Med"},{"issue":"11","key":"298_CR55","first-page":"1345","volume":"70","author":"R Khater","year":"1986","unstructured":"Khater R et al. Cisplatin plus 5-fluorouracil in the treatment of metastatic anal squamous cell carcinoma: a report of two cases. Cancer Treat Rep. 1986;70(11):1345\u20136.","journal-title":"Cancer Treat Rep"},{"issue":"6","key":"298_CR56","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1097\/00000421-199312000-00017","volume":"16","author":"IA Jaiyesimi","year":"1993","unstructured":"Jaiyesimi IA, Pazdur R. Cisplatin and 5-fluorouracil as salvage therapy for recurrent metastatic squamous cell carcinoma of the anal canal. Am J Clin Oncol. 1993;16(6):536\u201340.","journal-title":"Am J Clin Oncol"},{"issue":"4\u20136","key":"298_CR57","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1007\/s11864-009-0103-7","volume":"9","author":"C Eng","year":"2008","unstructured":"Eng C, Pathak P. Treatment options in metastatic squamous cell carcinoma of the anal canal. Curr Treat Options Oncol. 2008;9(4\u20136):400\u20137.","journal-title":"Curr Treat Options Oncol"},{"key":"298_CR58","unstructured":"Eng C, et al. Choice of chemotherapy in the treatment of metastatic squamous cell carcinoma of the anal. 2012 Annual ASCO Meeting. J Clin Oncol 30, 2012 (suppl; abstr 4060). Available from: http:\/\/meetinglibrary.asco.org\/content\/100733-114 . This refers to currently available options for treating metastatic squamous cell carcinoma of anal canal."},{"key":"298_CR59","doi-asserted-by":"crossref","unstructured":"Rogers JE, et al. Definitive chemoradiation in oligometastatic squamous cell carcinoma of the anal canal. Gastrointest Cancer Res. 2014.","DOI":"10.1007\/s12029-014-9626-7"},{"issue":"4","key":"298_CR60","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1177\/030089161009600419","volume":"96","author":"S Dosso De","year":"2010","unstructured":"De Dosso S et al. Molecular characterization and response to cetuximab in a patient with refractory squamous cell anal carcinoma. Tumori. 2010;96(4):627\u20138.","journal-title":"Tumori"},{"issue":"5","key":"298_CR61","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1159\/000259615","volume":"77","author":"N Lukan","year":"2009","unstructured":"Lukan N et al. Cetuximab-based treatment of metastatic anal cancer: correlation of response with KRAS mutational status. Oncology. 2009;77(5):293\u20139.","journal-title":"Oncology"},{"key":"298_CR62","unstructured":"NIH, N.I.o.H. International multicentre study in advanced anal cancer comparing cisplatin plus 5 FU vs carboplatin plus weekly paclitaxel (InterAACT). 2014 [cited 2014 02\/11\/2014].Available at: http:\/\/clinicaltrials.gov\/ct2\/show\/NCT02051868?term=InterAACT&rank=1 . This is the only phase II comparison trial to evaluate the different chemotherapy regimens for metastatic anal cancer."},{"key":"298_CR63","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1186\/1471-2407-10-189","volume":"10","author":"N Damme Van","year":"2010","unstructured":"Van Damme N et al. Epidermal growth factor receptor and K-RAS status in two cohorts of squamous cell carcinomas. BMC Cancer. 2010;10:189.","journal-title":"BMC Cancer"},{"key":"298_CR64","unstructured":"Paliga AA, et al. KRAS and EGFR gene mutation status in anal canal carcinoma. 2010 Gastrointestinal Cancers Symposium. General Poster Session C: Cancers of the Colon and Rectum. Abstr 352. Available from: http:\/\/meetinglibrary.asco.org\/content\/2056-72 ."},{"key":"298_CR65","doi-asserted-by":"crossref","unstructured":"Garg M, et al. Phase II trials of cetuximab (CX) plus cisplatin (CDDP), 5-fluorouracil (5-FU) and radiation (RT) in immunocompetent (ECOG 3205) and HIV-positive (AMC045) patients with squamous cell carcinoma of the anal canal (SCAC): safety and preliminary efficacy results. 2012 ASCO Annual Meeting Abstracts. J Clin Oncol. 2012, 30 (suppl 15; abstr 4030). Available from: http:\/\/meeting.ascopubs.org\/cgi\/content\/abstract\/30\/15_suppl\/4030 . This article is based on anti-EGFR roles on HIV negative and HIV patients with squamous cell carcinoma of the anal canal.","DOI":"10.1200\/jco.2012.30.15_suppl.4030"},{"key":"298_CR66","unstructured":"Deutsch E, et al. Cetuximab plus radiochemotherapy in locally advanced anal cancer: Interim results of the French multicenter phase II trial ACCORD16. 2011 ASCO Annual Meeting. General Poster Session, Gastrointestinal (Noncolorectal) Cancer. J Clin Oncol. 2011, 29 (suppl; abstr 4098). Available from: http:\/\/meetinglibrary.asco.org\/content\/81933-102 ."},{"issue":"10","key":"298_CR67","doi-asserted-by":"crossref","first-page":"728","DOI":"10.7326\/0003-4819-148-10-200805200-00005","volume":"148","author":"P Patel","year":"2008","unstructured":"Patel P et al. Incidence of types of cancer among HIV-infected persons compared with the general population in the United States, 1992-2003. Ann Intern Med. 2008;148(10):728\u201336.","journal-title":"Ann Intern Med"},{"issue":"10","key":"298_CR68","doi-asserted-by":"crossref","first-page":"1496","DOI":"10.1007\/BF02234605","volume":"44","author":"JH Kim","year":"2001","unstructured":"Kim JH et al. HIV-positive patients with anal carcinoma have poorer treatment tolerance and outcome than HIV-negative patients. Dis Colon Rectum. 2001;44(10):1496\u2013502.","journal-title":"Dis Colon Rectum"},{"issue":"15","key":"298_CR69","doi-asserted-by":"crossref","first-page":"2550","DOI":"10.1200\/JCO.2007.15.2348","volume":"26","author":"C Oehler-Janne","year":"2008","unstructured":"Oehler-Janne C et al. HIV-specific differences in outcome of squamous cell carcinoma of the anal canal: a multicentric cohort study of HIV-positive patients receiving highly active antiretroviral therapy. J Clin Oncol. 2008;26(15):2550\u20137.","journal-title":"J Clin Oncol"},{"key":"298_CR70","doi-asserted-by":"crossref","unstructured":"Rubinstein P, et al. Concurrent chemoradiotherapy with 5-fluorouracil and mitomycin-C for invasive anal carcinoma in HIV-positive patients receiving highly active anti-retroviral therapy versus non-HIV patients. 2012 ASCO Annual Meeting. J Clin Oncol 30, 2012 (suppl; abstr e14590). Available from: http:\/\/meetinglibrary.asco.org\/content\/101205-114 . This study compares the outcomes of HIV negative patients with anal cancer who receive chemoradiation versus HIV positive patients with anal cancer who receive chemoradiation and HAART.","DOI":"10.1200\/jco.2012.30.15_suppl.e14590"},{"issue":"5","key":"298_CR71","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.1016\/S0360-3016(96)00596-2","volume":"37","author":"AV Peddada","year":"1997","unstructured":"Peddada AV et al. Chemotherapy and low-dose radiotherapy in the treatment of HIV-infected patients with carcinoma of the anal canal. Int J Radiat Oncol Biol Phys. 1997;37(5):1101\u20135.","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"1","key":"298_CR72","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/S0360-3016(98)00528-8","volume":"44","author":"R Hoffman","year":"1999","unstructured":"Hoffman R et al. The significance of pretreatment CD4 count on the outcome and treatment tolerance of HIV-positive patients with anal cancer. Int J Radiat Oncol Biol Phys. 1999;44(1):127\u201331.","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"1","key":"298_CR73","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1016\/j.ijrobp.2006.03.049","volume":"66","author":"S Edelman","year":"2006","unstructured":"Edelman S, Johnstone PA. Combined modality therapy for HIV-infected patients with squamous cell carcinoma of the anus: outcomes and toxicities. Int J Radiat Oncol Biol Phys. 2006;66(1):206\u201311.","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"8","key":"298_CR74","doi-asserted-by":"crossref","first-page":"1305","DOI":"10.1007\/s10350-004-0584-1","volume":"47","author":"RF Stadler","year":"2004","unstructured":"Stadler RF et al. Outcome of HIV-infected patients with invasive squamous-cell carcinoma of the anal canal in the era of highly active antiretroviral therapy. Dis Colon Rectum. 2004;47(8):1305\u20139.","journal-title":"Dis Colon Rectum"},{"key":"298_CR75","unstructured":"National Comprehensive Cancer Network, N. Anal Carcinoma, NCCN guidelines. 2014 (Version 2.2013). This refers to the current guidelines for the management of anal cancer in the United States."}],"container-title":["Current Treatment Options in Oncology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11864-014-0298-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11864-014-0298-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11864-014-0298-0","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,8,22]],"date-time":"2020-08-22T03:15:18Z","timestamp":1598066118000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11864-014-0298-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,7,10]]},"references-count":75,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2014,9]]}},"alternative-id":["298"],"URL":"https:\/\/doi.org\/10.1007\/s11864-014-0298-0","relation":{},"ISSN":["1527-2729","1534-6277"],"issn-type":[{"value":"1527-2729","type":"print"},{"value":"1534-6277","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,7,10]]}}}